Protecting Mammalian Hair Cells from Aminoglycoside-Toxicity: Assessing Phenoxybenzamine's Potential by Majumder, P et al.
ORIGINAL RESEARCH
published: 18 April 2017
doi: 10.3389/fncel.2017.00094
Protecting Mammalian Hair Cells
from Aminoglycoside-Toxicity:
Assessing Phenoxybenzamine’s
Potential
Paromita Majumder1*, Paulette A. Moore1, Guy P. Richardson2 and Jonathan E. Gale1,3*
1UCL Ear Institute, University College London, London, UK, 2Sussex Neuroscience, School of Life Sciences, University of
Sussex, Falmer, UK, 3Department of Cell and Developmental Biology, University College London, London, UK
Edited by:
Peter S. Steyger,
Oregon Health & Science University,
USA
Reviewed by:
Allison B. Coffin,
Washington State University, USA
Federico Kalinec,
University of California, Los Angeles,
USA
*Correspondence:
Paromita Majumder
paromita.majumder@gmail.com
Jonathan E. Gale
j.e.gale@ucl.ac.uk
Received: 01 February 2017
Accepted: 20 March 2017
Published: 18 April 2017
Citation:
Majumder P, Moore PA,
Richardson GP and Gale JE
(2017) Protecting Mammalian Hair
Cells from Aminoglycoside-Toxicity:
Assessing Phenoxybenzamine’s
Potential.
Front. Cell. Neurosci. 11:94.
doi: 10.3389/fncel.2017.00094
Aminoglycosides (AGs) are widely used antibiotics because of their low cost and
high efficacy against gram-negative bacterial infection. However, AGs are ototoxic,
causing the death of sensory hair cells in the inner ear. Strategies aimed at developing
or discovering agents that protect against aminoglycoside ototoxicity have focused
on inhibiting apoptosis or more recently, on preventing antibiotic uptake by the
hair cells. Recent screens for ototoprotective compounds using the larval zebrafish
lateral line identified phenoxybenzamine as a potential protectant for aminoglycoside-
induced hair cell death. Here we used live imaging of FM1-43 uptake as a proxy
for aminoglycoside entry, combined with hair-cell death assays to evaluate whether
phenoxybenzamine can protect mammalian cochlear hair cells from the deleterious
effects of the aminoglycoside antibiotic neomycin. We show that phenoxybenzamine
can block FM1-43 entry into mammalian hair cells in a reversible and dose-dependent
manner, but pre-incubation is required for maximal inhibition of entry. We observed
differential effects of phenoxybenzamine on FM1-43 uptake in the two different types
of cochlear hair cell in mammals, the outer hair cells (OHCs) and inner hair cells (IHCs).
The requirement for pre-incubation and reversibility suggests an intracellular rather than
an extracellular site of action for phenoxybenzamine. We also tested the efficacy of
phenoxybenzamine as an otoprotective agent. In mouse cochlear explants the hair cell
death resulting from 24 h exposure to neomycin was steeply dose-dependent, with
50% cell death occurring at ∼230 µM for both IHC and OHC. We used 250 µM
neomycin in subsequent hair-cell death assays. At 100 µM with 1 h pre-incubation,
phenoxybenzamine conferred significant protection to both IHCs and OHCs, however
at higher concentrations phenoxybenzamine itself showed clear signs of ototoxicity and
an additive toxic effect when combined with neomycin. These data do not support the
use of phenoxybenzamine as a therapeutic agent in mammalian inner ear. Our findings
do share parallels with the observations from the zebrafish lateral line model but they
also highlight the necessity for validation in the mammalian system and the potential for
differential effects on sensory hair cells from different species, in different systems and
even between cells in the same organ.
Keywords: hair cells, cochlea, aminoglycosides, ototoxicity, FM 1-43, organotypic culture, mechanoelectrical
transduction channels, inner ear
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INTRODUCTION
Aminoglycosides (AGs) are widely used antibiotics because of
their low cost and high efficacy against gram-negative bacterial
infection. AGs are both nephrotoxic (Toubeau et al., 1986; Hock
and Anderson, 1995) and ototoxic (Greenwood, 1959) affecting
the vestibular and auditory organs (Matz et al., 2004). Among the
AGs neomycin is highly toxic, particularly in the hearing organ,
the cochlea (Forge and Schacht, 2000). In the cochlea, AGs first
affect the high-frequency hair cells found at the basal end of the
cochlea, subsequently extending to the lower-frequency regions
at the apical end of cochlear spiral (Aran and Darrouzet, 1975;
Stebbins et al., 1979; for review see Forge and Schacht, 2000).
In order to access the apical surface of hair cells AGs must
first pass through the blood labyrinth barrier which is composed
of a highly specialized capillary network in the stria vascularis
(Shi, 2016). Studies with fluorescently-tagged gentamicin showed
that it travels from the stria vascularis capillaries into marginal
cells and then into the endolymph (Wang and Steyger, 2009;
Wang et al., 2010) at which point it comes into contact with
the apical surface of the hair cells. AGs can enter into hair cells
via an endocytic route (Hashino and Shero, 1995) or via the
mechanotransduction (MET) channels, located in the hair cell’s
stereociliary bundle (Gale et al., 2001; Marcotti et al., 2005; Dai
et al., 2006; Wang and Steyger, 2009; Alharazneh et al., 2011) a
route that is facilitated by the low calcium concentration of the
endolymph (Marcotti et al., 2005).
When mammalian cochlear hair cells die there is no
endogenous regenerative process that can replace them and thus
hearing loss is permanent. Stem cell based therapies are being
pursued and may well be available in the longer term. In the
shorter term, however, it is important that we discover therapies
that might protect hair cells from damage and death as a result of
ototoxic medication, noise-induced hearing loss and aging.
New aminoglycoside antibiotics derived from the structural
backbones of existing AGs are being produced to generate less
ototoxicity whilst still being effective antibiotics (Matt et al.,
2012; Duscha et al., 2014; Shulman et al., 2014; Huth et al.,
2015). Until such antibiotics are available, a protective agent
that could be applied along with any known ototoxin would
be very advantageous. There have been a number of screens
to identify compounds that might confer hair-cell protection
during ototoxicity, including screens of FDA-approved drugs
that could bypass some of the approval requirements (Ou
et al., 2009). Many of these have used the zebrafish lateral
line system as a screening model. One of the compounds
that came through two separate screens using two different
sets of FDA-approved compounds was phenoxybenzamine
(also known as N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)
benzylamine hydrochloride or dibenzyline) which was one of
seven drugs which showed protection against aminoglycoside-
induced hair-cell death potentially by blocking aminoglycoside
uptake by hair cells (Ou et al., 2009; Vlasits et al., 2012). In
zebrafish it was noted that pre-incubation of phenoxybenzamine
was required to see efficacy in increasing hair-cell survival
(Vlasits et al., 2012). Although phenoxybenzamine is a well
characterized drug that is known to cross the blood brain barrier
(Diop and Dausse, 1986) and so perhaps the blood labyrinth
barrier, it has not been tested on mammalian cochlear hair cells.
Phenoxybenzamine is a well-known alpha-1-A and alpha-2-A
adrenergic receptor antagonist (Thoenen et al., 1964). Among
alpha 1-A and 2-A receptors, phenoxybenzamine has a slow
onset and long lasting effect compared with other alpha
adrenergic blockers and it is used to reduce the vasoconstriction
caused by epinephrine (adrenaline) and norepinephrine.
Phenoxybenzamine acts by covalently binding to the receptor
resulting in the inhibition of ligand binding. It is used to
reduce the hypertension caused by pheochromocytoma, for
lower urinary tract problems (e.g., neurogenic bladder; Te,
2002), benign prostatic hyperplasia (Kumar and Dewan, 2000)
and in complex regional pain syndrome (Inchiosa, 2013).
Phenoxybenzamine is also known to block 5-HT2 serotonin
receptors (Frazer and Hensley, 1999), in some cases acting as an
irreversible blocker (Doggrell, 1995).
In this study we evaluated whether the protective effects
of phenoxybenzamine that are observed in zebrafish hair
cells (Ou et al., 2009; Vlasits et al., 2012) are also observed
in mammalian inner hair cells (IHCs) and outer hair cells
(OHCs). We first investigated the effects of phenoxybenzamine
on the rapid FM1-43 entry into hair cells that occurs
via the mechanoelectrical-transduction channels and mimics
aminoglycoside entry (Gale et al., 2001). Second, we tested
whether phenoxybenzamine could protect hair cells during
neomycin ototoxicity.
MATERIALS AND METHODS
Materials
Phenoxybenzamine hydrochloride was obtained from Santa Cruz
Biotechnology, Dallas, TX, USA and neomycin and ciprofloxacin
from Sigma-Aldrich, UK. Leibovitz’s L15 (L15), DMEM/F12,
FM1-43FX and fetal bovine serum (FBS) were acquired from
ThermoFisher scientific, UK and the cell and tissue adhesive
Cell-Tak was supplied by BD Biosciences, UK. All other
chemicals were obtained from Sigma-Aldrich, UK.
Postnatal Cochlea Isolation and Culture
In accordance with the United Kingdom Animals (Scientific
Procedures) Act of 1986 (Schedule 1 procedures), cochleae were
extracted from C57BL/6 wild-type mice at postnatal day 3–6
(P3-P6). The isolated cochleae were micro-dissected in Leibovitz
L15 medium. The apical cochlear turn was discarded and the
remaining 1.5 turns separated into ‘‘middle’’ and ‘‘basal’’ coils.
The stria-vascularis was kept in place and Reissner’s membrane
was cut allowing the cochlear coils to be ‘‘fileted’’ open and
then placed onto Cell-Takr coated Matek (Ashland, MA, USA)
dishes (Majumder et al., 2015). Explant cultures were incubated
in DMEM/F12 supplemented with 1% FBS and ciprofloxacin
(10 µg/ml) at 37◦C in a 5% CO2/95% air atmosphere overnight
prior to experimentation.
Live FM1-43 Imaging and Analysis
All experiments were conducted at room temperature (20–22◦C).
FM1-43 (6 µM) was prepared from a 10 mM stock solution.
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The control culture was loaded with 6 µM FM1-43 for 30 s
and then immediately washed (five 10 s washes, followed by
three slower, 2 min washes) in L15 or HBHBSS prior to imaging
with a Zeiss 510NLO upright confocal microscope (excitation
488 nm, emission 500–550 nm) using a 40× (NA 0.8) water
immersion objective. Confocal image stacks (∼20 planes, 2 µm
intervals) were acquired exactly 20min after exposure to FM1-43.
The confocal laser power and gain settings were identical for
all live imaging experiments to enable data comparison. To
evaluate whether phenoxybenzamine was more effective when
pre-incubated, in a subset of experiments it was applied for 30 or
60 min prior to FM1-43 loading and the loading was performed
in the continued presence of phenoxybenzamine (including
the washout solution). To test for reversibility of the block,
after 30 min of phenoxybenzamine incubation explants were
washed for varying amounts of time before testing with FM1-
43. Images were analyzed using ImageJ (NIH, USA). A running
two frame average was applied to the Z planes and to maintain
consistency ROIs were drawn two planes (i.e., ∼4 µm) below
the FM1-43 fluorescence signal from the hair-cell stereocilia.
ROIs covered the extent of the cell body in that plane. Average
intensities from the ROIs were recorded and the background
fluorescence (measured in a non-cellular region) was subtracted.
Measurements were taken from 30 OHCs and 10 IHCs per
explant.
Ototoxic Hair Cell Death and Protection
Assay
To determine a dose-response curve, middle and basal coil
cochlear explants were exposed to 0, 10, 100, 200, 250,
400 or 1000 µM neomycin for 24 h. To determine whether
phenoxybenzamine confers protection against neomycin
ototoxicity, cochlear explants were pre-treated for 1 h in
0, 50, 100 or 200 µM phenoxybenzamine followed by
24 h co-treatment in phenoxybenzamine and 250 µM
neomycin in DMEM/F12 media at 37◦C in a 5% CO2/95%
air atmosphere. After all experiments, explants were fixed with
4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS,
pH 7.2) at room temperature for 30–45 min for immunostaining
and later evaluation for pyknotic and surviving hair cells.
Immunohistochemistry, Image Acquisition
and Analysis
After fixation the explants were rinsed three times with PBS
and incubated in blocking solution (PBS, 10% secondary host
antibody serum and 0.5% Triton X-100) for 2 h. Subsequently,
the explants were incubated with a mouse monoclonal
anti-myosin 7A antibody, deposited to the DSHB by Orten,
D.J. (DSHB Hybridoma Product MYO7A 138-1, used at 1:250)
or a rabbit polyclonal anti-myosin 7A (25–6790, Proteus
BioScience, used at 1:1000) primary antibody in blocking
solution overnight at 4◦C. Samples were then washed in PBS
and incubated for 2 h at room temperature with 4′,6′-diamidino-
2-phenylindole (DAPI 1 µM), AlexaFluor647 phalloidin
(33 nM) and goat anti-rabbit-Atto488 or goat anti-mouse-
Atto488 secondary antibodies in blocking solution. The explants
were rinsed three times with PBS and imaged using the
multiphoton Zeiss 510 NLO upright confocal microscope. DAPI
was imaged using the a two-photon Chameleon-XR Ti:Sapphire
laser tuned to 720 nm (435–485 nm bandpass filter), Atto488 was
imaged using the 488 nm (500–550 nm bandpass filter) and
AlexaFluor647 phalloidin using the 633 nm (long pass filter
650 nm) laser lines. Images were acquired at 1.5 µm Z intervals
using either Achroplan 40× (NA 0.8) or Achroplan 63× Vis-IR
(NA 1.0) water immersion objectives.
Z stacks (25–30 planes, 1.5 µm intervals) were acquired
from two different regions in each explant. Image stacks were
visualized using ZEN Lite software (Carl Zeiss Ltd, Germany)
to identify pyknotic and surviving hair cells. The hair cells were
considered pyknotic when they presented with condensed and
marginated chromatin in the nuclei (Li et al., 1995; Lahne and
Gale, 2008). Here we have used the characteristic pattern of
pyknosis that we observe with the DAPI and myosin 7A staining
during the death of IHCs and OHCs (Figure 1).
Hair cells with normal nuclei were considered to be viable
surviving hair cells. Counts from the two regions sampled were
averaged so that each explant counted as one N sample. Images
were independently evaluated by two individuals.
Statistics
For live imaging experiments, all the data are presented as the
mean ± SEM and ANOVA was applied with post hoc Tukey-
Kramer’s with significance set at p < 0.05. For hair-cell survival
and pyknosis, all the data are presented as the mean ± SEM and
the statistical test used was Students’s t-test with significance set
as p< 0.05.
RESULTS
Phenoxybenzamine Blocks Rapid FM 1-43
Entry in Mammalian Hair Cells if
Preincubated
To evaluate the nature of phenoxybenzamine’s interaction with
mammalian MET channels, we measured FM1-43 uptake by hair
cells in cochlear explant cultures from postnatal day 3–6 mice. A
brief (30 s) exposure to FM1-43 ensured that rapid entry through
the MET channels was the primary uptake pathway as opposed
to a slower endocytic mechanism. FM1-43 uptake was hair cell
specific and irreversible with OHCs taking up approximately
twice as much FM1-43 as IHCs as described previously (Gale
et al., 2001). When 100 µM phenoxybenzamine was simply
co-applied during FM-143 exposure there was no significant
effect on FM1-43 uptake in either IHCs or OHCs. In contrast,
when phenoxybenzamine was also pre-incubated for either 30 or
60 min, we found a significant reduction in FM1-43 uptake in
OHCs, and a small reduction in uptake in IHCs that failed to
reach significance (Figures 2A,B). Pre-incubation substantially
reduced FM1-43 uptake to 28% of control levels in OHCs and
60% in IHCs respectively, significantly different to uptake both
in the controls and in samples in which compounds were co-
applied together (Figure 2C). The block of FM1-43 uptake was
reversible upon washout although the recovery from block was
not immediate. Comparing a 1 min washout with a 60 min
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FIGURE 1 | Progression of neomycin-induced hair cell death. A
sequence of images representing different stages of cell death that are
observed after 24 h of neomycin exposure for both outer hair cells (OHCs) (A)
and inner hair cells (IHCs) (B). Anti-myosin 7A labeling (upper panel),
4′,6′-diamidino-2-phenylindole (DAPI) staining of nuclear chromatin (middle
panel), Myo7A/DAPI merged image (lower panel). Since individual cells
undergo cell death at different times each cell is at a different stage in the cell
death process and the images have been compiled into a pseudo-time series
as indicated by the arrows. Scale bar 5 µm.
washout we can see that the recovery was ∼15% in OHCs after
1 min but was complete after 60 min (Figure 3). Recovery
appeared to be faster but more variable in IHCs and on average
we observed an overshoot in the recovery, but we note that the
blocking effect of phenoxybenzamine was less robust in IHCs
than in OHCs.
In order to determine whether the blockade of FM1-43
entry was dose-dependent, we varied the concentrations of
phenoxybenzamine from 0 µM to 200 µM, pre-incubating for
30 min prior to FM1-43 application. The IC50 for the block of
FM1-43 uptake by phenoxybenzamine differed slightly between
OHC (logIC50 −4.185, 65 µM) and IHC (logIC50 −4.424,
38 µM) however, the Hill coefficient was strikingly different
being 4 for OHC and 0.9 for IHC (Figure 4). One simple
interpretation of these data is that there is a difference in the
molecular nature of the MET channel in the two cochlear hair
cell types. An alternative explanation is that the MET channel
activity is reduced indirectly via a process that is affected by
phenoxybenzamine and that is more prevalent in OHCs.We note
that higher concentrations of phenoxybenzamine could not be
tested due to problems with solubility that have been reported by
others (Nisa et al., 2010).
Phenoxybenzamine Can Protect Hair Cells
from Neomycin-Induced Ototoxicity
For the next experiments we set out to determine a concentration
of neomycin that gave us ≥50% toxicity in our mouse cochlear
explant culture model after 24 h of exposure. Cochlear explants
were treated with neomycin at a range of concentrations from
0 µM to 1000 µM. At the end of the 24-h exposure explants
were fixed and triple-labeled with DAPI, fluorescent phalloidin
and antibodies to myosin 7A. Z-stack images were then collected
using a confocal microscope (Figure 5A). Since hair cells are
known to be able to survive without a hair bundle (Gale et al.,
2002), we focused our analysis on the hair-cell soma and nuclear
chromatin markers, as shown in Figure 1, to quantify the
number of surviving hair cells, using the image stacks. A steep
dose-dependence was observed for neomycin-induced hair cell
death for both OHC and IHC (Figure 5B), with 50% cell death
constants of 228 µM (log −3.642) and 232 µM (log −3.635)
and different Hill coefficients of 4.7 and 1.9, respectively. Based
on these experiments we decided to use 250 µM neomycin
in subsequent experiments to test whether phenoxybenzamine
could provide any protection in this 24 h ototoxicity model.
Given the requirement for drug pre-incubation, in test
explants phenoxybenzamine (50, 100 or 200 µM) was applied
for 1 h prior to the addition of neomycin in the presence
of phenoxybenzamine. After 24 h explants were fixed, the
same triple-labeling protocol was applied to all explants and
image stacks collected and analyzed to quantify the number
of surviving and pyknotic hair cells. At a concentration of
50 µM phenoxybenzamine did not offer significant protection
against neomycin-induced ototoxicity (data not shown). In
the presence of 100 µM phenoxybenzamine, however, the
number of surviving OHC and IHC per 100 µm length
of the cochlea was significantly higher, 27.9 ± 3.5 and
9.0± 1.0 respectively, compared to 17.6± 3.1 and 5.0± 1.4 with
neomycin alone (p < 0.05). Using either the untreated control
or phenoxybenzamine-treated alone explants to calculate the
percent survival reveals that phenoxybenzamine increased OHC
survival from 47% to 86% and IHC survival from 46% to 98%
(Figure 6). Although phenoxybenzamine significantly reduced
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FIGURE 2 | Phenoxybenzamine (PB) significantly reduces rapid FM1-43 uptake in OHCs but not in inner cells. (A) Confocal images of FM1-43 uptake
after brief exposure (30 s) in OHCs (upper panels) and IHCs (lower panel) under control conditions (left panel), either when co-applied with 100 µM PB (middle panel)
or when explants were pre-incubated in PB for 30 min prior to FM1-43 application (right panel). (B) Quantification of FM1-43 fluorescence reveals that pre-incubation
with phenoxybenzamine for 30 min or 60 min significantly reduces uptake in OHCs but not IHCs. Maximal inhibition of FM1-43 uptake is achieved in 30 min.
(C) Pre-incubating with phenoxybenzamine is significantly more effective at blocking the rapid uptake of FM1-43. Expressed as a % of control, the uptake was
reduced from 66% to 28% in OHCs and from 97% to 60% in IHCs. N numbers: control = 12; 100 µM PB-co-app = 6; 30 min pre-incubation = 9; 60 min
pre-incubation = 6. Statistical test: ANOVA Tukey-Kramer’s test, ∗p < 0.05 in (B); Student’s t-test, ∗p < 0.05 in (C).
the number of neomycin-induced pyknotic OHC nuclei, we
also observed a small but significant increase in pyknotic
OHC and IHC nuclei when phenoxybenzamine was applied
alone indicating the potential toxicity of the drug in the
cochlea. The phenoxybenzamine-induced toxicity was more
evident, particularly in OHCs at the highest concentration used
(200 µM). In addition we observed that at 200 µM, rather
than protecting hair cells against neomycin, phenoxybenzamine
significantly enhanced the neomycin-induced toxicity in OHCs,
whereas enhancement of toxicity was not observed in IHC
(Supplementary Figure S1).
DISCUSSION
Phenoxybenzamine was one of a small number of compounds
identified from two high-throughput drug screens for neomycin
ototoxicity using zebrafish larvae (Ou et al., 2009; Vlasits
et al., 2012). In zebrafish lateral line hair cells, the blockade
of neomycin uptake into hair cells is thought to be the
primary mode of action for the otoprotective effect of
phenoxybenzamine (Ou et al., 2009). Here we used mammalian
cochlear explant cultures from postnatal mice to evaluate the
possible otoprotective effect of phenoxybenzamine. Testing
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FIGURE 3 | Phenoxybenzamine block of FM1-43 entry is reversible.
(A) After a 30 min pre-incubation in 100 µM phenoxybenzamine explants were
washed for 1 min or 60 min in HBSS before being exposed to 6 µM FM1-43
for 30 s. Confocal images of the FM1-43 fluorescence signal in OHCs (upper
panels) and IHCs (lower panel) when applied at 0 s, 1 min or 60 min after
phenoxybenzamine washout. (B) The block by phenoxybenzamine is
completely reversed 60 min after wash out. The fractional recovery of the
FM1-43 signals was calculated from F recov = (F − Fmin)/(Fmax − Fmin), where
Fmin is the signal from 30 min pre-incubation (n = 9) and Fmax = control (no
phenoxybenzamine) signal (n = 12) and F = 1 min (4) or 60 min (6). A F recov
value of 1 is equal to control (Fmax). Student’s t-test; ∗p < 0.05.
compounds in the mammalian system is critical given the
clear differences between the mammalian cochlea and the
lateral line, not least because there are two distinctly different
types of hair cell in the cochlea. We first characterized the
effect of phenoxybenzamine on rapid FM1-43 uptake, which
we use as mimic of neomycin entry since it permeates
the mechanoelectrical transducer channels and has been
shown to reduce the toxic effects of neomycin (Gale et al.,
2001).
In zebrafish hair cells phenoxybenzamine blocks the uptake
of both FM1-43 and gentamicin-Texas Red (Ou et al., 2009;
Vlasits et al., 2012). We now show that phenoxybenzamine can
block FM1-43 entry in both IHCs and OHCs in the mammalian
cochlea. The IC50 for the blocking effect was quite similar
between the two hair cell types (40–60 µM), however there was a
∼4 fold difference in the Hill coefficient with the block in OHCs
showing a steep dependence indicating cooperative binding,
whereas in IHCs the coefficient was close to 1 suggesting
non-cooperative binding of phenoxybenzamine. To better
understand the mode of action, we compared pre-incubation
of phenoxybenzamine with simple co-application and found
that maximal inhibition was achieved by pre-incubation
(Figure 2) as previously described in zebrafish (Vlasits
et al., 2012). A 30 min pre-incubation was already maximal
and no further block was observed when we extended the
time of incubation to 60 min. Phenoxybenzamine is known
FIGURE 4 | Phenoxybenzamine block of FM1-43 entry is
dose-dependent. (A) Confocal images of rapid FM-143 uptake assessed
after 30 min of pre-incubation in 10, 50 or 200 µM phenoxybenzamine.
Images at the focal planes of the OHC and IHC are shown. (B) Quantification
of the rapid FM1-43 uptake in the presence of different concentrations of
phenoxybenzamine reveal the reduction in FM1-43 uptake as a function of
increasing phenoxybenzamine concentration in both OHC (red) and IHC (blue).
The IC50 and Hill coefficient values from the curve fits are provided in the main
text. N numbers: control (12); 10 µM PB (3); 50 µM PB (4); 100 µM (9);
200 µM (4). Scale bar: 20 µm.
to bind covalently to adrenergic receptors and serotonin
receptors and in zebrafish the hair-cell survival effected
by phenoxybenzamine persisted after phenoxybenzamine
washout (Ou et al., 2009). In our live FM1-43 uptake assay,
although the phenoxybenzamine effect remained for the first
minute (at least in OHCs), the block was fully reversible after
60 min of washout. We observed differences in the effect of
phenoxybenzamine on FM1-43 uptake in OHCs and IHCs.
If the site of action of phenoxybenzamine in mammalian
hair cells is within the mechanoelectrical transduction
channel itself, this would suggest that there are significant
differences in the structure of the channel between IHC
and OHCs. Given the pre-incubation requirement, a simple
explanation for this could that there is an intracellular
binding site for phenoxybenzamine that is not present in
IHCs. An alternative and perhaps more likely explanation is
that there may be indirect effects of phenoxybenzamine on
the mechanoelectrical transduction channels via regulatory
molecules that are more prevalent in OHCs compared to
IHCs.
We next examined whether the otoprotection seen in
the lateral line with phenoxybenzamine is also observed in
mammalian cochlear hair cells. The effects of AGs are both
time and dose-dependent and we first set out to determine a
neomycin-dose response curve for 24 h of exposure in our mouse
cochlear explant model. We found a steep dose-dependence for
neomycin-induced hair cell-death, particularly for OHCs (Hill
coefficient of 4.7 compared to 1.9 in IHCs, Figure 5). The IC50 or
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FIGURE 5 | Steep dose-dependent increase in hair-cell death after 24 h exposure to neomycin. (A) Confocal images of three different cellular markers:
phalloidin, labeling F-actin; myosin7A (Myo7A), for the hair cell soma and DAPI which showing nuclear condensation and pyknosis in neomycin-treated examples.
The right hand panels show a higher magnification (zoom) of the DAPI label in the IHC region. (B) Quantification of the numbers of surviving hair cells (expressed per
100 µm) reveals the steep dose-dependency of neomycin toxicity after 24 h of drug exposure. The 50% cell-death constants are similar between OHC (228 µM) and
IHC (232 µM) but the Hill coefficients were quite different (4.7 and 1.9 respectively). N numbers: 0.1 µM (10); 10 µM (9); 100 µM (9); 200 µM (5); 250 µM (9);
400 µM (8); 1000 µM (10). Scale bar: 20 µm.
50% cell-death constant for neomycin was ∼250 µM for both
OHCs and IHCs and we used this concentration in subsequent
assays in order to promote∼50% hair cell loss/survival, allowing
either a protective effect or an enhancement of hair-cell death to
be identified.
When used at a concentration of 100 µM phenoxybenzamine
produced a significant protection of both OHC and IHCs,
resulting in survival of both OHCs (86% survival) and IHCs
(98% survival) relative to controls, i.e., phenoxybenzamine
treatment alone. A small amount of toxicity was noted
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FIGURE 6 | Phenoxybenzamine confers protection against neomycin ototoxicity. (A) Representative confocal images showing the protective effect of the
100 µM phenoxybenzamine on the neomycin-induced hair cell death in both OHC and IHC. Images for phenoxybenzamine alone (PB), neomycin-alone for 250 µM
for 24 h (Neo) or pre-incubation and continued presence of phenoxybenzamine during the neomycin exposure (Neo+PB). Images showing condensed chromation
and pyknotic nuclei (DAPI staining, arrows) and the absence of the myosin7A labeling in missing/damaged hair cells. (B) Quantification of IHC and OHC survival (from
myosin7A, upper graphs) and pyknotic hair cell nuclei (from DAPI images, lower graphs) in control C, 250 µM neomycin-treated (N), phenoxybenzamine alone
(C+PB) or neomycin and phenoxybenzamine treated (N+PB) explants. N numbers: Neo (11); Neo+PB (8); PB alone (9); control (10). ∗p < 0.05 (compared to control).
Scale bar, 20 µm.
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in the phenoxybenzamine-alone controls, based on the
assessment of nuclear chromatin and pyknosis (Figures 1,
6). At a higher concentration, 200 µM phenoxybenzamine
in combination with neomycin produced different effects on
the two types of hair cell. The IHCs were still protected but
there was an enhancement of toxicity in OHCs indicating
an additive effect of phenoxybenzamine and neomycin.
When phenoxybenzamine was applied alone at 200 µM for
24 h it resulted in a small amount of OHC death but did
not affect IHCs. The stronger block of FM1-43 uptake in
OHCs compared to IHCs that we have shown could explain
the differential toxicity if we assume that activity of the
MET channels is essential for cell survival. Another possible
explanation for the phenoxybenzamine-induced toxicity
observed in OHCs is that it results from the differential
expression of known phenoxybenzamine targets. We checked
cochlear gene expression on gEAR portal1 and found that both
serotonin receptors and adrenergic receptors are differentially
expressed by OHCs and IHCs (Liu et al., 2014) providing
some support for this as an alternative hypothesis for the
observed toxicity. Importantly, however, phenoxybenzamine
protects both IHCs and OHCs from neomycin-induced
toxicity and the simplest explanation is that this is due to a
reduction in neomycin uptake via the MET channels, consistent
with our FM1-43 uptake assay (a mimic for the neomycin
uptake).
The lack of a significant effect of phenoxybenzamine on
FM1-43 uptake in IHCs compared to OHCs, but the presence of
a protective effect from neomycin suggests a greater complexity
here. The primary pathway for the aminoglycoside entry into
hair cells is now considered to be via the MET channels located
at the top of the stereocilia, consistent with AGs acting as
open-channel blockers (Kroese et al., 1989; Ricci, 2002; Marcotti
et al., 2005) as described for FM1-43 (Gale et al., 2001). However,
the contribution of other ion channels to the uptake of AGs
into hair cells has been less well characterized. Channels such
as the transient receptor potential (TRP) class members such
as TRPC3, TRPV4, TRPA1 and PRPML3 which are expressed
in the cochlea have not been ruled out as possible entry
pathways (Castiglioni and García-Añoveros, 2007; Cuajungco
et al., 2007; Asai et al., 2010; Stepanyan et al., 2011; Quick
et al., 2012). AGs block a variety of ion channels such as
large-conductance Ca2+-activated K+ channels (Nomura et al.,
1990), N-type and P/Q type Ca2+ channels (Pichler et al.,
1996), ryanodine receptors (Mead and Williams, 2002a,b), P2X
receptors (Lin et al., 1993) and nicotinic acetylcholine receptors
(Blanchet et al., 2000). Similar to its effects on the MET channels,
FM1-43 is also known to block TRPC3/TRPC6 channels
(Quick et al., 2012). Phenoxybenzamine could be affecting any
of the above channels, however, investigating these different
ion channels is outside of the remit of this current work.
In these present experiments a somewhat unexpected result
was the consistent difference we observed between IHC and
OHCs. Differences in the nature of the MET channels between
these two cell types have been described (Beurg et al., 2006,
1http://umgear.org/index.html
2009) and although the our results were generated from a
different type of assay, they support the possibility of there
being alternative channel isoforms expressed in the two cell
types.
In recent years high-throughput screening in
non-mammalian models has proven to be very useful in
identify new compounds for preventing hair-cell death.
The data presented here indicate the importance of follow
up studies in mammalian hair-cell models. Our study did
identify consistency between results from zebrafish lateral
line screens and the mammalian cochlea: from the mode
of action of phenoxybenzamine on FM1-43 uptake to the
requirement for pre-incubation to achieve maximal inhibition.
The particular sensitivity of OHCs to phenoxybenzamine is,
however, something that would tend to preclude its clinical
use. Nonetheless, the differential effects of phenoxybenzamine
on IHC and OHCs could turn out to be of significance in our
understanding of the molecular mechanisms regulating MET
channels.
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FIGURE S1 | Higher concentrations of phenoxybenzamine confer
some protection against neomycin ototoxicity for IHCs but are toxic to
OHCs. (A) Quantification of hair cell survival in the presence of 200 µM
phenoxybenzamine (PB) alone or in the presence of neomycin for both IHCs
and OHCs. N numbers: Neo (11); control (4); Neo+PB 50 µM (4); 50 µM PB
alone (4); Neo+PB 200 µM (5); 200 µM PB alone (4). ∗P < 0.05 and
∗∗P < 0.005. (B) Representative confocal images showing F-actin (phalloidin),
myosin 7a (Myo7a), for the hair cell soma and DAPI showing nuclear
condensation and pyknosis in neomycin-treated examples.
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